biote Corp. (BTMD) Q3 2024 Earnings Call Transcript
- biote Corp. (NASDAQ:BTMD ) Q3 2024 Earnings Call November 12, 2024 5:00 PM ET Company Participants Szymon Serowiecki - Investor Relations Terry Weber - Chief Executive Officer Bob Peterson - Chief Financial Officer Conference Call Participants Jonna Kim - Cowen Jeff Van Sinderen - B. Riley Kaumil Gajrawala - Jefferies Les Sulewski - Truist Securities George Kelly - ROTH Capital Partners Operator Welcome to the biote Third Quarter 2024 Earnings Conference Call.
- 11/13/2024
|
Biote Corp. (BTMD) Beats Q3 Earnings Estimates
- Biote Corp. (BTMD) came out with quarterly earnings of $0.33 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to loss of $0.11 per share a year ago.
- 11/12/2024
|
Wall Street Analysts See an 88.04% Upside in biote Corp. (BTMD): Can the Stock Really Move This High?
- The consensus price target hints at an 88% upside potential for biote Corp. (BTMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- 11/01/2024
|
Is biote Corp. (BTMD) a Great Value Stock Right Now?
- Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- 10/28/2024
|
biote Corp. (BTMD) Q2 2024 Earnings Call Transcript
- biote Corp. (NASDAQ:BTMD ) Q2 2024 Earnings Conference Call August 8, 2024 5:00 PM ET Company Participants Szymon Serowiecki – Investor Relations Terry Weber – Chief Executive Officer Bob Peterson – Chief Financial Officer Conference Call Participants Les Sulewski – Truist Securities Jonna Kim – TD Cowen Richard Magnusen – B. Riley Securities George Kelly – ROTH Capital Kaumil Gajrawala – Jefferies Operator Good day, and welcome to the Biote Second Quarter 2024 Earnings Conference Call.
- 08/10/2024
|
Buy These 4 Stocks With Rising Cash Flows for Big Gains
- Cash indicates a company's true financial health. It is the key to its existence, development and success.
- 08/08/2024
|
biote Corp. (BTMD) is on the Move, Here's Why the Trend Could be Sustainable
- biote Corp. (BTMD) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
- 07/25/2024
|
Buy 4 Stocks With Rising Cash Flows to Enrich Your Portfolio
- Achieving profit is, no doubt, a company's goal, but having a healthy cash flow is imperative to its existence, development and success. So, ASC, TXO, GPRK and BTMD are worth buying.
- 07/24/2024
|
5 Stocks With Recent Price Strength to Tap Wall Street Rally
- Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are ADMA, AMSC, BTMD, LINC, CORT.
- 07/17/2024
|
Wall Street Analysts Think biote Corp. (BTMD) Could Surge 25.44%: Read This Before Placing a Bet
- The average of price targets set by Wall Street analysts indicates a potential upside of 25.4% in biote Corp. (BTMD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 07/09/2024
|
biote Corp. (BTMD) is on the Move, Here's Why the Trend Could be Sustainable
- biote Corp. (BTMD) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
- 07/09/2024
|
biote Corp. (BTMD) Surges 10.4%: Is This an Indication of Further Gains?
- biote Corp. (BTMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
- 06/24/2024
|
Biote Announces $60 Million Agreement to Repurchase 8.3 Million Shares and Cancel Approximately 4.0 Million Earnout Shares
- IRVING, Texas--(BUSINESS WIRE)--biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced it has signed a binding term sheet with Marci M. Donovitz, stockholder of Biote, to resolve litigation (“Donovitz Litigation”). For $60 million in the aggregate, Biote will repurchase all of the approximately 8.3 million of the Paired Interests and/or Class.
- 06/20/2024
|
biote Corp. (BTMD) Q1 2024 Earnings Call Transcript
- biote Corp. (NASDAQ:BTMD ) Q1 2024 Earnings Conference Call May 7, 2024 5:00 PM ET Company Participants Simon Serowiecki - Investor Relations Terry Weber - Chief Executive Officer Bob Peterson - Chief Financial Officer Marc Beer - Executive Chairman Ross McQuivey - Chief Medical Officer Conference Call Participants Les Sulewski - Truist Securities Jonna Kim - TD Cowen Kaumil Gajrawala - Jefferies George Kelly - ROTH MKM Operator Good day, and welcome to the Biote First Quarter 2024 Earnings Conference Call. [Operator Instructions] Please note, this event is being recorded.
- 05/09/2024
|
Biote Corp. (BTMD) Q1 Earnings Beat Estimates
- Biote Corp. (BTMD) came out with quarterly earnings of $0.23 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to earnings of $0.94 per share a year ago.
- 05/07/2024
|
Biote Reports First Quarter 2024 Financial Results
- IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Highlights (All financial result comparisons made are against the prior-year period) Revenue of $46.8 million, up 4.4% Procedure revenue of $37.4 million, up 6.6% Gross profit margin of 71.4%, an app.
- 05/07/2024
|
Earnings Preview: biote Corp. (BTMD) Q1 Earnings Expected to Decline
- Biote Corp. (BTMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/30/2024
|
Biote Announces Definitive Settlement with Founder
- IRVING, Texas--(BUSINESS WIRE)--biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced it has entered into a definitive settlement agreement (the “Settlement Agreement”) that concludes outstanding litigation with Dr. Gary S. Donovitz (“Donovitz”), founder and stockholder of Biote. The Settlement Agreement includes a mutual release of all clai.
- 04/29/2024
|
Biote Schedules First Quarter 2024 Financial Results Release and Conference Call
- IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide first quarter financial results on Tuesday, May 7, 2024, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call may be a.
- 04/23/2024
|
This overlooked corner of women's health could be a $350 billion market opportunity
- Menopause is among the female health conditions with the highest unmet need and has 'enormous potential for innovative treatments,' according to McKinsey.
- 03/15/2024
|
biote Corp. (BTMD) Q4 2023 Earnings Call Transcript
- biote Corp. (BTMD) Q4 2023 Earnings Call Transcript
- 03/12/2024
|
Biote Reports Fourth Quarter and Full Year 2023 Financial Results
- IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter 2023 Financial Highlights (All financial result comparisons made are against the prior-year period) Revenue of $45.7 million, a 2.7% increase and in line with pre-released financial guidance Proc.
- 03/12/2024
|
Analysts Estimate biote Corp. (BTMD) to Report a Decline in Earnings: What to Look Out for
- Biote Corp. (BTMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 03/05/2024
|
Biote Announces $20 Million Share Repurchase Authorization
- IRVING, Texas--(BUSINESS WIRE)--biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that its Board of Directors has approved a $20 million share repurchase program of the Company's common stock. This approval grants Biote's management the authority to repurchase outstanding shares of the Company's common stock, from time to time, in the op.
- 01/25/2024
|
Biote to Purchase Asteria Health
- IRVING, Texas--(BUSINESS WIRE)--biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced a definitive agreement to acquire F.H. Investments, Inc., d/b/a Asteria Health, a privately held 503B manufacturer of compounded bioidentical hormones. The company operates an FDA-registered 503B outsourcing facility in Birmingham, Alabama and currently sup.
- 01/17/2024
|
Biote Provides Preliminary 2023 Results and Initial 2024 Guidance
- IRVING, Texas--(BUSINESS WIRE)--biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that management expects 2023 revenue and Adjusted EBITDA to be slightly below prior guidance. The Company had previously forecast that revenue and Adjusted EBITDA would be toward the lower end of the previously announced ranges of $190-$200 million and $56-.
- 01/17/2024
|
Biote Names Robert Peterson as Chief Financial Officer
- IRVING, Texas--(BUSINESS WIRE)--biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that Robert Peterson has been named Chief Financial Officer, effective January 8, 2024. Mr. Peterson will lead Biote's finance operations, including accounting and controllership, financial planning and analysis, financial reporting, internal audit, tax, tr.
- 01/11/2024
|
biote Should Keep Delivering Strong Growth
- biote Corp. returned to profitability in Q3 2023 and is expected to continue to be profitable in the future. The company's growth is driven by the sale of hormone replacement therapy products and its expansion into complementary wellness products. BTMD is considered undervalued and has an aggressive price target for the end of next year.
- 11/29/2023
|
Biote Corp. (BTMD) Reports Q3 Loss, Lags Revenue Estimates
- Biote Corp. (BTMD) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of $0.08. This compares to loss of $0.09 per share a year ago.
- 11/07/2023
|
Biote Reports Third Quarter 2023 Financial Results
- IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced financial results for the third quarter ended September 30, 2023. Third Quarter 2023 Financial Highlights (All financial result comparisons made are against the prior year period) Revenue of $45.6 million, an 8.5% increase Gross profit margin of 68.9%, a 70-basis point increase Net income of $19.6 million, representing.
- 11/07/2023
|
Biote Schedules Third Quarter 2023 Financial Results Release and Conference Call
- IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading provider of hormone optimization, today announced the Company will provide third quarter financial results on Tuesday, November 7, 2023, after the close of the market. A conference call to discuss the firm's results will be held Wednesday, November 8, 2023, at 8:30 a.m. ET. Conference Call Details The conference call may be accessed by dialing (844) 481-2820 (U.S toll-free) or (412) 317-0679 (Intern.
- 10/24/2023
|
Biote Corp. (BTMD) Beats Q2 Earnings and Revenue Estimates
- Biote Corp. (BTMD) came out with quarterly earnings of $0.44 per share, beating the Zacks Consensus Estimate of $0.10 per share. This compares to earnings of $0.27 per share a year ago.
- 08/10/2023
|
Biote Reports Second Quarter 2023 Financial Results
- IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced financial results for the second quarter ended June 30, 2023. Second Quarter 2023 Financial Highlights (All financial result comparisons made are against the prior year period) Revenue of $49.3 million, a 19.1% increase Gross profit margin of 67.9%, a 60-basis point increase Net loss of $(13.1) million and GAAP loss pe.
- 08/10/2023
|
Recent Price Trend in biote Corp. (BTMD) is Your Friend, Here's Why
- If you are looking for stocks that are well positioned to maintain their recent uptrend, biote Corp. (BTMD) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
- 07/18/2023
|
biote Corp. (BTMD) Moves 5.3% Higher: Will This Strength Last?
- biote Corp. (BTMD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- 07/12/2023
|
Biote Schedules First Quarter 2023 Financial Results Release and Conference Call
- IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading provider of preventive health care through the delivery of personalized hormone therapy, today announced the Company will provide first quarter financial results on Tuesday, May 9, 2023, after the close of the market. A conference call to discuss the firm's results will be held Wednesday, May 10, 2023, at 8:30 a.m. ET. Conference Call Details The conference call may be accessed by dialing (844) 481-.
- 04/26/2023
|
Does biote Corp. (BTMD) Have the Potential to Rally 82.51% as Wall Street Analysts Expect?
- The mean of analysts' price targets for biote Corp. (BTMD) points to an 82.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- 03/31/2023
|
Biote Schedules Fourth Quarter and Full Year 2022 Financial Results Release and Conference Call
- IRVING, Texas--(BUSINESS WIRE)--Biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading provider of preventive health care through the delivery of personalized hormone therapy, today announced the Company will provide fourth quarter and full year financial results on Tuesday, March 28, 2023, after the close of the market. A conference call to discuss the firm's results will be held Wednesday, March 29, 2023 at 8:30 a.m. ET.
- 02/09/2023
|
Biote Schedules Third Quarter 2022 Financial Results Release and Conference Call
- IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading provider of preventive health care through the delivery of personalized hormone therapy, today announced the Company will provide third quarter financial results on Tuesday, November 8, 2022, after the close of the market.
- 10/31/2022
|
Biote to Report Second Quarter 2022 Financial Results on August 9, 2022 and Host Conference Call on August 10, 2022
- IRVING, Texas--(BUSINESS WIRE)--biote Corp. (“Biote” or the “Company”) (Nasdaq: BTMD), a high growth, medical practice-building business within the hormone optimization space, will report its financial results for the second quarter ended June 30, 2022, after market close on Tuesday, August 9, 2022. Terry Weber, Chief Executive Officer, and the Company's management will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET on Wednesday, August 10
- 07/20/2022
|
